ÂÜÀòÂÒÂ×

Keith Dawkins spent nine years at Boston Scientific Corporation, a $60B medical device company, in a variety of leadership roles, including Global Chief Medical Officer & Executive Vice President; Chief Medical Officer & Senior Vice President, Cardiology, Rhythm & Vascular; Associate Chief Medical Officer & Vice President, Medical Sciences. As Global Chief Medical Officer & Executive Vice President, he was a member of the Boston Scientific Executive Committee, acting as the Voice of the Patient. He oversaw the clinical function for all six Divisions, as well as leading Medical Affairs in Europe and Latin America, Health Economics in Europe, and Pre-Clinical Sciences for the company. He has worked closely with Regulators, including the FDA, PMDA, and European Agencies. He was Chairman of the Clinical Governance Committee, which provides oversight for all clinical trials undertaken within the company, and he also initiated the Investigator Sponsored Research program which is now in widespread use across all the divisions. He was intimately involved in the Boston Scientific Mergers & Acquisition Strategy, as well as the strategic direction of the clinical trials portfolio. Additionally, he worked closely with the Investor Relations group. During his time at BSC, he transformed the clinical function, improving the strategic and managerial alignment between clinical sciences and the divisions, as well as instigating a robust outsourcing and offshoring process for clinical trial implementation.

Since leaving BSC in early 2017, he remains active in the MedTech sector as a Board Member of Avicena LLC, a Board Member of JenaValve Technology Inc, Chairman of the Board of InnovHeart s.r.l, Senior Advisor to Conformal Medical Inc, and Venture Partner of XGEN Venture SGR S.p.A. He was Chief Medical Officer & Senior Advisor to 4Tech Inc (2017-2020).